Page last updated: 2024-08-24

topotecan and Neutropenia

topotecan has been researched along with Neutropenia in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	18 (20.00)	18.2507
2000's	58 (64.44)	29.6817
2010's	14 (15.56)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belani, C; Cristea, MC; Gandara, DR; Gitlitz, BJ; Goldkorn, A; Gong, IY; Groshen, SG; Kelly, K; Koczywas, M; Liu, SV; Newman, EM; Reckamp, KL; Semrad, TJ; Synold, TW; Xu, T; Xu, Y	1
Agelaki, S; Bompolaki, I; Chandrinos, V; Georgoulias, V; Kalbakis, K; Kontopodis, E; Kotsakis, A; Papadimitraki, E; Stoltidis, D; Zafeiriou, Z	1
Chakravarty, A; Mettetal, JT; Palani, S; Patel, M; Shyu, WC; Yang, J	1
Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM	1
Bianco, V; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Martellucci, I; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L	1
Horita, N; Ikeda, M; Kaneko, T; Kobayashi, N; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M	1
Bodnar, L; Gasowska-Bodnar, A; Nasilowska, A; Smoter, M; Szarlej-Wcislo, K; Szczylik, C; Wcislo, G	1
Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW	1
Anagnostopoulos, A; Antoniou, D; Ardavanis, A; Athanasiadis, A; Koutantos, J; Papadopoulos, G; Papakotoulas, P; Pectasides, D; Stathopoulos, GP; Trafalis, D; Vaslamatzis, M	1
Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM	1
Andreopoulou, E; Blank, S; Chen, T; Curtin, J; Hochster, H; Liebes, L; Muggia, F; Wallach, R	1
Conkling, P; Fitzgibbons, JF; Galsky, MD; Jotte, R; Klein, L; McNally, R; Oliver, JW; Renschler, MF; Reynolds, C	1
Chikamori, K; Harita, S; Hosokawa, S; Hotta, K; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Shibayama, T; Shinkai, T; Tabata, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Ueoka, H	1
Carter, JS; Downs, LS	1
Billups, CA; Brennan, R; Free, TM; Given, V; Haik, BG; Helton, K; McCarville, MB; Merchant, TE; Qaddoumi, I; Rodriguez-Galindo, C; Stewart, CF; Tagen, M; Wilson, MW; Wu, J	1
DeBernardo, RL; Eaton, SM; Frasure, HE; Fusco, NL; Heugel, AM; Smith, DA; von Gruenigen, VE; Waggoner, SE	1
Fife, K; Gordon, MS; Hanna, NH; Sandler, AB	1
Goldwasser, F; Gross-Goupil, M; Hasbini, A; Lokiec, F; Lopez, G; Misset, JL; Romain, D; Tigaud, JM	1
Chak, K; Chan, AT; Johnson, P; Lee, TW; Leung, TW; Mok, TS; Wong, H; Yeo, W; Yim, A; Yu, KH; Zee, B	1
Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P	1
Anders, K; Feldmann, HJ; Fietkau, RJ; Grabenbauer, GG; Klautke, G; Krauseneck, P; Sauer, R; Staab, HJ; Weiser, S	1
Brown, JV; Drescher, CW; Graham, CL; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Birch, R; Campos, L; Hainsworth, J; Schnell, F; Tongol, J; West, W	1
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D	1
Alberts, DS; Berek, JS; Garcia, DJ; Gold, MA; Hallum, AV; Walker, JL	1
Baselga, J; Carrato, A; Domine, M; Felip, E; Font, A; Garrido, P; Mañe, JM; Rosell, R; Santomé, L; Terrasa, J; Vadell, C	1
Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA	1
Berlin, J; Boothman, D; Forouzannia, A; Hutson, P; Mehta, M; Schiller, J; Storer, B; Wilding, G	1
Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE	1
Ansell, SM; Green, EM; Mahoney, MR; Rubin, J	1
Holcombe, RF; Kong, KM; Wimmer, D	1
Biamonte, R; Cartenì, G; Danese, S; De Laurentiis, M; De Matteis, A; De Placido, S; Di Vagno, G; Febbraro, A; Gallo, C; Gasparini, G; Greggi, S; Lauria, R; Lombardi, AV; Manzione, L; Marinaccio, M; Naglieri, E; Perrone, F; Pignata, S; Scambia, G; Valerio, MR	1
Bugat, R; Chatelut, E; Goffinet, M; Léger, F; Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J	1
Anand, A; Chan, SY	1
Briasoulis, E; Karavassilis, V; Mauri, D; Pavlidis, N; Pentheroudakis, G; Rammou, D; Tzamakou, E	1
Buchholz, E; Gatzemeier, U; Goetz, E; Groth, G; Manegold, C; Reck, M	1
Curtin, JP; Dellenbaugh, C; Hamilton, A; Hochster, H; Lee, S; Liebes, L; Mirchandani, D; Muggia, FM; Sorich, J; Yee, H	1
Armstrong, DK; Lane, S; Levin, J; Poulin, R; Spriggs, D	1
Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M	1
Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW	1
Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA	1
Gosse, H; Huber, RM; Kleinschmidt, R; Mezger, J; Reck, M; Saal, JG; Steppert, C; Steppling, H; von Pawel, J	1
Alberti, D; Arzoomanian, R; Binger, K; Dubey, S; Feierabend, C; Hutson, P; Schiller, JH; Volkman, J; Wilding, G	1
Armand, JP; Djafari, L; Djazouli, K; Faivre, S; Ghesquières, H; Lhommé, C; Lozahic, S; Pautier, P; Raymond, E	1
Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J	1
Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J	1
Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E	1
Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D	1
Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR	1
Cui, BX; Jiang, J; Kong, BH; Meng, LH; Su, SL; Wang, B; Wang, LJ; Yang, XS; Zhang, YZ	1
Bonneterre, J	1
Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL	1
Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ	1
Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J	1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR	1
Beijnen, JH; Dennis, MJ; Grochow, LB; van Warmerdam, LJ	1
Janik, JE; Saltz, L	1
Robert, F; Soong, SJ; Wheeler, RH	1
Benedetti, JK; Macdonald, JS; Natale, RB; O'Rourke, MA; Wall, JG	1
Burris, HA; Eckardt, JR; Raymond, E; Rodriguez, G; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, G	1
Batist, G; Bernard, S; Egorin, MJ; Hollis, DR; Lilenbaum, RC; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H	1
Abbruzzese, JL; Ellis, AL; Hess, KR; Loughlin, S; Madden, T; Newman, RA; Raber, MN; Sugarman, SM; Zwelling, LA	1
Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N	1
Beran, M; Kantarjian, H	1
Cacciari, N; Martoni, A; Zamagni, C	1
Alvarez, RD; Blessing, JA; Hall, K; Hanjani, P; Markman, M; Waggoner, S	1
Anderson, H; Carrington, B; Cheeseman, S; Hearn, S; Ranson, M; Ross, G; Thatcher, N; White, SC	1
Brouwer, E; de Jonge, MJ; Doyle, E; Gelderblom, H; Hearn, S; Loos, WJ; Mantel, MA; Planting, AS; Ross, G; Sparreboom, A; van Beurden, V; van der Burg, ME; Verweij, J	1
Fleming, GF; Janisch, L; Ratain, MJ; Ryan, CW	1
Blessing, JA; Kilgore, LC; Mannel, R; Miller, DS; Van Le, L	1
Hansen, HH; Herrstedt, J; Hirsch, FR; Jensen, PB; Sorensen, M	1
Dubuc-Lissoir, J; Eisenhauer, E; Fisher, B; Grimshaw, R; Hoskins, P; Oza, A; Plante, M; Stuart, G; Vergote, I; Vermorken, J	1
Coughlin, C; Curran, WJ; Fisher, BJ; Macdonald, DR; Scott, C	1
Adams, AL; Boente, M; Bookman, MA; Ciccotto, S; Gallo, JM; Millenson, MM; Ozols, RF; Padavic-Shallers, K; Rogatko, A; Rogers, B; Rosenblum, N; Schilder, RJ; Weiner, LM	1
Bildat, S; Camlett, I; Gatzemeier, U; Lane, S; Moreau, L; Pujol, JL; Ranson, M; Richardson, G; Rivière, A; Ross, G; Steppert, C; von Pawel, J	1
Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ	1
Brunetti, C; Carreca, I; Comella, G; Comella, P; DeCataldis, G; Frasci, G; Muci, D; Natale, M; Nicolella, G; Palmeri, S; Panza, N; Piantedosi, F; Russo, A	1
Bowman, A; Ross, G; Rye, T; Smyth, JF; Wheatley, A	1
Barnes, B; Brierre, J; Buller, E; Cole, J; Fontenot, F; Lormand, N; Rainey, J; Rinaldi, D	1
D'Argenio, DZ; Delauter, BJ; Egorin, MJ; Farese, AM; Kubat, NM; MacVittie, T; Potter, DM; Stewart, CF; Tubergen, D; Zamboni, WC	1
Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Palamidas, P; Raptis, A	1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N	1
Bolis, G; Guarnerio, P; Parazzini, F; Polverino, GP; Rosa, C; Scarfone, G; Sciatta, C	1
Giaccone, G; Huisman, C; Postmus, PE; Smit, EF	1
Ames, MM; Krailo, MD; Mares, WL; Mosher, R; Reaman, GH; Reid, JM; Seibel, NL; Wells, RJ; Wiersma, SR	1
Beijnen, JH; Holford, NH; Hutson, PR; Mould, DR; Rosing, H; Ross, G; Rowinsky, EK; Russo, M; Schellens, JH; Schiller, JH; ten Bokkel Huinink, WW	1
Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE	1

Reviews

6 review(s) available for topotecan and Neutropenia

Article	Year
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Scientific reports, 2016, Jan-11, Volume: 6 Topics: Anthracyclines; Antineoplastic Agents; Asian People; Humans; Japan; Lung Neoplasms; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; White People	2016
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topotecan	2005
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]. Bulletin du cancer, 1995, Volume: 82, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting	1995
An overview of the clinical pharmacology of topotecan. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lactones; Metabolic Clearance Rate; Models, Chemical; Neutropenia; Solubility; Topoisomerase I Inhibitors; Topotecan; Water	1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clinical pharmacology and therapeutics, 2002, Volume: 71, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Confidence Intervals; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Models, Chemical; Neoplasms; Neutropenia; Probability; Topotecan	2002

Trials

75 trial(s) available for topotecan and Neutropenia

Article	Year
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Thrombocytopenia; Topotecan; Treatment Failure; Treatment Outcome	2018
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Palliative Care; Small Cell Lung Carcinoma; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	2013
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2015
Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:6 Topics: Alopecia; Anemia; Antineoplastic Agents; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Vomiting	2009
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult	2009
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. Anti-cancer drugs, 2010, Volume: 21, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2010
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Lactones; Middle Aged; Neutropenia; Ovarian Neoplasms; Remission Induction; Stomach Neoplasms; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2011
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; United States	2011
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:1 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2011
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. International journal of clinical oncology, 2011, Volume: 16, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Thalidomide; Topotecan	2011
Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer, 2012, Nov-15, Volume: 118, Issue:22 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neutropenia; Retinal Neoplasms; Retinoblastoma; Survival Rate; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; Vincristine	2012
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. Anti-cancer drugs, 2012, Volume: 23, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anemia; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Uterine Neoplasms	2012
Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies. American journal of clinical oncology, 2002, Volume: 25, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Recombinant Proteins; Survival Analysis; Topotecan; Vinblastine; Vinorelbine	2002
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Synergism; Female; Fever; Humans; Infections; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Patient Dropouts; Thrombocytopenia; Topotecan; Treatment Outcome	2002
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer, 2002, Oct-01, Volume: 95, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan	2002
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 38, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome	2002
Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study. Journal of neuro-oncology, 2002, Volume: 60, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiotherapy, Conformal; Sepsis; Sinusitis; Thrombocytopenia; Topotecan	2002
Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecologic oncology, 2003, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Recombinant Proteins; Topotecan	2003
Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. The oncologist, 2003, Volume: 8, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Topotecan; Treatment Outcome	2003
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecologic oncology, 2003, Volume: 90, Issue:2 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neutropenia; Topotecan	2003
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2003
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2004
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 44, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Diarrhea; Esophagitis; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Thoracic Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome	2004
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	2004
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. American journal of clinical oncology, 2004, Volume: 27, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Islet Cell; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Topotecan	2004
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer. Anti-cancer drugs, 2004, Volume: 15, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting	2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	2004
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Chemotherapy, 2005, Volume: 51, Issue:2-3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Topotecan	2005
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liposomes; Male; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome; Vomiting	2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncology reports, 2005, Volume: 14, Issue:6 Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan	2006
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2006, Volume: 47, Issue:6 Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. The European respiratory journal, 2006, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Neutrophils; Organoplatinum Compounds; Platelet Count; Retreatment; Survival Rate; Topotecan; Treatment Outcome	2006
Phase I study of docetaxel and topotecan in patients with advanced malignancies. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Taxoids; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Investigational new drugs, 2006, Volume: 24, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	2006
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome	2007
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan	2006
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan	2006
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer]. Zhonghua fu chan ke za zhi, 2007, Volume: 42, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan; Treatment Outcome	2007
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan	1994
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States	1995
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	1995
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan	1996
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States	1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting	1997
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. American journal of clinical oncology, 1997, Volume: 20, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan	1997
Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Investigational new drugs, 1997, Volume: 15, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Inhibitors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	1997
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	1997
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	1998
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Skin Diseases; Thrombocytopenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome; Vomiting	1996
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan	1999
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Seminars in hematology, 1999, Volume: 36, Issue:4 Suppl 8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Platelet Count; Remission Induction; Risk Assessment; Survival Rate; Thrombocytopenia; Topotecan	1999
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support? European journal of gynaecological oncology, 2000, Volume: 21, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan	2000
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecologic oncology, 2000, Volume: 77, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Palliative Care; Thrombocytopenia; Topotecan; Treatment Outcome	2000
Phase II study of oral topotecan in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting	2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	2000
A phase I study of liposomal doxorubicin (Doxil) with topotecan. American journal of clinical oncology, 2000, Volume: 23, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan	2000
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Cohort Studies; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leiomyosarcoma; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia; Topotecan; Uterine Neoplasms	2000
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	2000
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epithelium; Feasibility Studies; Female; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan; Vomiting	2000
Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Topotecan	2001
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Topotecan	2001
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neutropenia; Topotecan; Treatment Outcome	2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome	2001
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. British journal of cancer, 2001, May-04, Volume: 84, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Topotecan	2001
Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-01, Volume: 19, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Survival Rate; Topotecan	2001
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer investigation, 2001, Volume: 19, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome	2001
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan	2001
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology, 2001, Volume: 61, Issue:4 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2001
A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecologic oncology, 2001, Volume: 83, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	2001
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2001
Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Rhabdomyosarcoma; Salvage Therapy; Topotecan; Treatment Outcome	2002
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	1992

Other Studies

9 other study(ies) available for topotecan and Neutropenia

Article	Year
Dose schedule optimization and the pharmacokinetic driver of neutropenia. PloS one, 2014, Volume: 9, Issue:10 Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Male; Models, Biological; Models, Theoretical; Neutropenia; Rats, Sprague-Dawley; Taxoids; Topotecan	2014
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2015
[Hematological toxicity of some combined chemotherapy schemes involving aranoza]. Eksperimental'naia i klinicheskaia farmakologiia, 2010, Volume: 73, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan	2010
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. The journal of obstetrics and gynaecology research, 2003, Volume: 29, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure	2003
Mechanism-based models for topotecan-induced neutropenia. Clinical pharmacology and therapeutics, 2004, Volume: 76, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Female; Humans; Injections, Intravenous; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Nonlinear Dynamics; Reproducibility of Results; Topotecan	2004
The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience. Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Medical Audit; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2004
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan	2006
Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan	2007
Pharmacodynamic model of topotecan-induced time course of neutropenia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Disease Models, Animal; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Neutrophils; Recombinant Proteins; Time Factors; Topoisomerase I Inhibitors; Topotecan	2001